KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) EBT Margin (2017 - 2025)

Historic EBT Margin for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to 115.23%.

  • Bionano Genomics' EBT Margin rose 6129400.0% to 115.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 134.24%, marking a year-over-year increase of 2731100.0%. This contributed to the annual value of 363.87% for FY2024, which is 2797000.0% up from last year.
  • As of Q3 2025, Bionano Genomics' EBT Margin stood at 115.23%, which was up 6129400.0% from 101.69% recorded in Q2 2025.
  • Over the past 5 years, Bionano Genomics' EBT Margin peaked at 47.93% during Q1 2025, and registered a low of 1207.63% during Q3 2023.
  • Over the past 5 years, Bionano Genomics' median EBT Margin value was 445.07% (recorded in 2021), while the average stood at 419.51%.
  • In the last 5 years, Bionano Genomics' EBT Margin plummeted by -7675100bps in 2023 and then surged by 6129400bps in 2025.
  • Over the past 5 years, Bionano Genomics' EBT Margin (Quarter) stood at 455.66% in 2021, then rose by 1bps to 448.84% in 2022, then grew by 9bps to 409.73% in 2023, then surged by 40bps to 246.53% in 2024, then skyrocketed by 53bps to 115.23% in 2025.
  • Its EBT Margin was 115.23% in Q3 2025, compared to 101.69% in Q2 2025 and 47.93% in Q1 2025.